Cagrilintide 5mg
Metabolic support for body recomposition research.
Cagrilintide is a long-acting amylin analog studied alongside GLP-1 agonists in combination metabolic research. The Cagri-Sema and Cagri-Reta blends are the canonical dual-hormone research combinations.
Proposed mechanism
Cagrilintide activates both the amylin and calcitonin receptors — pathways involved in satiety signaling and gastric emptying, distinct from GLP-1 mechanisms. Combination with GLP-1 agonists is proposed to produce additive metabolic endpoints.
Research highlights
- Long-acting amylin analog
- Weekly dosing in research protocols
- Central to Cagri-Sema and Cagri-Reta combination research
- Complementary mechanism to GLP-1 agonism
Research protocol notes
Reconstitute under sterile technique with bacteriostatic water. Typical volumes range from 1–3 mL depending on the target working concentration. Swirl gently — do not shake — to avoid peptide shearing.
Stacking and comparative studies
Canonical stacks: cagrilintide + semaglutide (Cagri-Sema) or cagrilintide + retatrutide (Cagri-Reta). Pre-blended versions are available.
Handling and storage
Lyophilized powder is stable at ambient shipping temperatures. Once reconstituted with bacteriostatic water, store at 2–8 °C and use within 28 days. For long-term storage of unreconstituted vials, freeze at −20 °C and protect from light.
Frequently asked
What is amylin?
A peptide hormone co-secreted with insulin from pancreatic beta cells, involved in satiety and gastric-emptying regulation.
Why combine with semaglutide?
Different receptor pathways. Research proposes additive effects when amylin and GLP-1 pathways are activated together.
What is Cagri-Sema?
A pre-blended cagrilintide + semaglutide combination. Reduces reconstitution steps for comparative studies.
Weekly dosing?
Yes — the engineered half-life supports once-weekly research protocols.
